Company intelligence / Profile preview

ESCAPE Bio, Inc.

South San Francisco, California, USA6sense.com ↗

Ownership: Private
Employees: ~13
Development stage: Phase 1

Overview

ESCAPE Bio was a privately held biopharmaceutical company focused on developing small molecule therapies for genetically defined neurodegenerative diseases. Its lead programs included a Phase I study for ESB1609 targeting S1PRs in Niemann-Pick disease type C, an IND-enabling LRRK2 G2019S inhibitor for Parkinson's disease, and discovery-stage work on ApoE4 modulators for Alzheimer's disease. The company ceased operations in late 2022 or early 2023 before any product reached late-stage clinical trials.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

4 assets

Compound 34

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ESCAPE Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESCAPE Bio, Inc..

Explore the full profile